Creso Pharma has eye on North America with new crop of cannabis-credentialled executives

CANNANNEW REPORT

Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF) has launched the next stage of its growth strategy, appointing executives with strong backgrounds in the lucrative cannabis market. In a push to strengthen its executive team, CPH has appointed William Lay as CEO and managing director, leading cannabis and psychedelics entrepreneur Bruce Linton as a non-executive director and Micheline McKay as an executive director. CEO with growth ambition New CEO Lay was previously executive vice president overseeing strategy, origination and operations at Creso Pharma. Lay is an experienced cannabis executive who began his career in banking, with roles across Canada and London for BMO Capital Markets. He then joined Canopy Growth Corp, rising to associate director of Mergers & Acquisitions in 2019, where he oversaw multiple transactions locally and internationally, while progressing corporate strategy initiatives across the group. Over the last four years, Lay has managed and supported more than C$5 billion in cannabis M&A transactions, including leading the largest acquisition in the history of the cannabis sector. Eyeing North America In his new role, Lay will progress the company’s North American-focused growth strategy, as well as Creso Pharma’s proposed Nasdaq dual listing. He will also oversee the company’s global operations, including Creso Pharma’s Swiss division and potential new market entries. Creso Pharma plans to leverage his extensive expertise to assess strategic acquisitions in regions where it has an existing footprint, as well as for expansion purposes, with a particular focus on North America. Leading cannabis and psychedelics entrepreneur Bruce Linton co-founded and led Canopy Growth to become the first cannabis producer on the New York Stock Exchange. Lay and Linton worked closely together during their time at Canopy Growth, assessing, overseeing and executing more than C$5 billion in cannabis transactions, including the industry’s largest acquisition to date. “Importantly, Will, Bruce and Micheline are based in North America,” said chairman Dr…

Excerpt only …
READ MORE BELOW
Source : Creso Pharma has eye on North America with new crop of cannabis-credentialled executives

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.